GSK and Ionis secured US approval for Hibsago, a hepatitis B drug designed for a potential functional cure approach by targeting viral genetic instructions. The approval positions Hibsago as a first-in-class mechanism entry within chronic hepatitis B therapy, building on antisense oligonucleotide platform capabilities. The decision also reinforces how combination strategies—where functional cure concepts aim to achieve durable loss of viral replication—are moving from late-stage exploration into post-marketing reality. For biotech, the Hibsago approval illustrates continued regulatory openness to genetic targeting modalities in infectious diseases, even as companies still must define durable response benchmarks and longer-term durability endpoints.